Supercharged Immune Cells Show Promise Against HIV

Researchers are exploring a novel application of CAR-T cell therapy, a technique already successful in treating certain cancers, for its potential to combat HIV. The therapy involves genetically modifying a patient's T cells to better target and eliminate HIV-infected cells, while also equipping them with resistance to the virus.

Early-stage experiments have yielded provocative results, with two individuals exhibiting strong HIV suppression lasting nearly two years after a single dose of these enhanced CAR-T cells. This significantly reduces or eliminates the need for daily antiretroviral medications. These patients had started their HIV treatment early, suggesting a healthier immune system and less latent virus may improve outcomes.

While these findings are promising and suggest a potential path towards a one-and-done HIV cure, Dr. Steven Deeks, who led the research, emphasizes that larger, longer studies are crucial to validate the therapy's long-term effectiveness and safety. The data was presented at a meeting of the American Society of Gene and Cell Therapy.